BioAge Labs (BIOA) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioAge Labs (BIOA) has outperformed Bright Minds Biosciences (DRUG) over the past year, losing 50.5% versus a loss of 65.2%. Bright Minds Biosciences is the larger company by market cap ($201.2 million vs $196.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | DRUG |
|---|---|---|
| Share price | $4.28 | $20.40 |
| Market cap | $196.67M | $201.23M |
| 1-day change | -9.13% | -1.45% |
| YTD return | -67.65% | -73.86% |
| 1-year return | -50.52% | -65.18% |
| 5-year return | — | -7.27% |
| EPS (TTM) | $-2.56 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.99M | — |
| Net income (latest FY) | $-80.61M | — |
| Operating margin | -1031.46% | — |
| Net margin | -896.11% | — |
| 52-week high | $25.96 | $123.75 |
| 52-week low | $4.24 | $17.40 |
| Distance from 52-week high | -83.51% | -83.52% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +572.43% | +426.18% |
| Average volume | 740.06K | 173.24K |
| Shares outstanding | 45.95M | 9.86M |
| Employees | 60 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIOA has outperformed DRUG by 14.7 percentage points over the past year.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
BIOA vs DRUG FAQ
Which is bigger, BioAge Labs or Bright Minds Biosciences?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $201.23M compared with $196.67M for BioAge Labs (BIOA).
Which stock has performed better over the past year, BIOA or DRUG?
BIOA returned -50.52% over the past 12 months, compared with -65.18% for DRUG (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and Bright Minds Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.